AbbVie Pte Ltd, Research and Development, 9 North Buona Vista Drive, The Metropolis Tower One #19-01, Singapore 138588, Singapore.
Gustav Parmentier GmbH, Eichendorffstr. 37, 60320 Frankfurt am Main, Germany.
Int J Pharm. 2017 Oct 30;532(1):131-138. doi: 10.1016/j.ijpharm.2017.08.107. Epub 2017 Aug 30.
There has been limited research done on the downstream processing of nanosuspensions into solid oral dosage forms. This paper demonstrates the bead layering process with a layering level at 150% and 240%, as well as the selection and justification of the outer phase excipients for tabletability and disintegrating properties. In a previous study, an itraconazole nanosuspension stabilised by SDS and HPMC E5 was layered onto sugar beads with coating polymer HPMC VLV. In the current study, compression studies with these layered beads utilising the small bead size at 150% or 240% layering levels with outer phase cushioning excipients MCC, copovidone or isomalt were performed. Other excipients such as co-compressed crospovidone-PEG 4000; DCP functioning as a disintegrant; and HPC as a binder was also added. Target output variables were achieved with a balance between an adequate tensile strength and fast dissolution rate with a release of 99.0% (±1.0% SD) within 10min, which is in accordance with the FDA guidance for dissolution testing. The results show that the compaction of nanosuspension-layered beads is a suitable process for processing an itraconazole nanosuspension into a solid dosage form such as a compacted tablet without compromising on drug release.
对于将纳米混悬剂加工成固体口服剂型的下游处理,研究还很有限。本文展示了采用 150%和 240%的包衣水平的珠层工艺,以及选择和证明了外层辅料的可压性和崩解性能。在之前的研究中,用 SDS 和 HPMC E5 稳定的伊曲康唑纳米混悬液被包衣到 HPMC VLV 包衣聚合物的糖珠上。在当前的研究中,利用 150%或 240%包衣水平的小珠尺寸以及外层缓冲辅料 MCC、共聚维酮或异麦芽酮醇,对这些包衣珠进行了压缩研究。还添加了其他辅料,如共压缩的交联聚维酮-PEG4000;作为崩解剂的 DCP;以及作为粘合剂的 HPC。目标输出变量是通过在足够的拉伸强度和快速溶解速率之间取得平衡来实现的,在 10 分钟内释放 99.0%(±1.0%SD),这符合 FDA 对溶解试验的指导原则。结果表明,纳米混悬剂包衣珠的压缩是将伊曲康唑纳米混悬剂加工成固体剂型(如压片)的一种合适工艺,而不会影响药物释放。